We already know the answer to that... in how extraordinary the Rett placebo scores were, that unfortunately skewed the results. They were 4x better than the placebo arm in the trofinetide trial. Most unbelievable. But we also saw that blarcamesine performed 2.5x better than trofinetide. Most impressive.
Because of this extraordinary placebo "performance", the results weren't technically stat. sig. (though close), but QoL improvements and seizure reductions, as well as being a very safe drug, make it a successful trial. I'm confident that the RAs will also see it this way.
But we were talking about the AD P2b/3 trial that MET ALL ENDPOINTS.
News 
Market Data 
Discover 
